Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
-
CGP 37157 (HB1132)
Description:Potent, selective mitochondria Na+ / Ca2+ exchange inhibitor
Purity:>99%
-
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
-
Disulfiram (HB1119)
Description:Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor.
Purity:>97%
-
KB-R7943 mesylate (HB1133)
Description:Selective, reverse mode Na+ / Ca2+ exchange inhibitor
Purity:>99%
-
KN-62 (HB0359)
Description:Selective CaM kinase II inhibitor. P2X7 receptor antagonist.
Purity:>98%
-
-
MG132 (HB4135)
Description:Potent, cell-permeable proteasome inhibitor. Calpain inhibitor. Apoptosis inducer.
Purity:>95%
-
Paxilline (HB1056)
Description:Potent, reversible, selective KCa channel inhibitor. Also SERCA inhibitor.
Purity:>98%
